On May 1, 2023 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, reported that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences’ 2023 Frontiers in Cancer Immunotherapy meeting, taking place in New York, NY May 2-4, 2023 (Press release, Corbus Pharmaceuticals, MAY 1, 2023, View Source [SID1234630797]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation

Title:

CRB-601, an avβ8 blocking antibody, prevents activation of TGFβand exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment

Authors:

Daqing Wang, Ph.D; Vaishali Shinde, MS; Maneesh Singh, Ph.D.; Rachael Brake, Ph.D.; Andrew Kolodziej, Ph.D.

Date & Time:

May 3, 2023 at 4:30pm Eastern Time